X4 Pharmaceuticals Inc
XFOR
$1.29
Closing
▲4.88%
1D
▲53.85%
YTD
Market cap
$216.64M
52 week high
$2.58
52 week low
$0.57
Volume
282,567
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$216.64M
Analysts' Rating
BUY
Price Target (Mean)
3.45
Total Analysts
9
P/E
Operating Margin
0.00%
Beta
0.47
Revenue Growth (Annual)
0.00%
52 week high
$2.58
52 week low
$0.57
Div. Yield
%
EPS Annual Growth
-96.97
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
X4 Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery and development of therapies for people with diseases of the immune system. Its lead product candidate, mavorixafor, a small molecule antagonist of chemokine receptor C-X-C receptor type 4 (CXCR4), is being developed as an oral, once-daily therapy. Mavorixafor has the potential to provide therapeutic benefit across a variety of chronic neutropenic disorders, including warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a rare primary immunodeficiency. It also has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
